Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices. PURPOSE: To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes. DATA SOURCES: English-language studies from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, indexed from inception through March 2015 (MEDLINE search updated through December 2015). STUDY SELECTION: Paired reviewers independently identified 179 trials and 25 observational studies of head-to-head monotherapy or metformin-based combinations. DATA EXTRACTION: Two reviewers independently assessed study quality and serially extracted data and graded the strength of evidence. DATA SYNTHESIS: Cardiovascular mortality was lower for metformin versus sulfonylureas; the evidence on all-cause mortality, cardiovascular morbidity, and microvascular complications was insufficient or of low strength. Reductions in hemoglobin A1c values were similar across monotherapies and metformin-based combinations, except that DPP-4 inhibitors had smaller effects. Body weight was reduced or maintained with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors and increased with sulfonylureas, thiazolidinediones, and insulin (between-group differences up to 5 kg). Hypoglycemia was more frequent with sulfonylureas. Gastrointestinal adverse events were highest with metformin and GLP-1 receptor agonists. Genital mycotic infections were increased with SGLT-2 inhibitors. LIMITATION: Most studies were short, with limited ability to assess rare safety and long-term clinical outcomes. CONCLUSION: The evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). On the basis of less evidence, results for add-on therapies to metformin were similar to those for monotherapies. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compounds that modulate NF-κB signalling, including metformin137,235–237, apigenin238, kaempferol238 and BAY 11–7082 (REF.118), have also been shown to decrease SASP production.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [236]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We evaluated the heterogeneity among the trials by using the I(2) statistic (11).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We generated summary treatment effects with the random-effects model estimated by using the DerSimonian and Laird method in settings of low heterogeneity (I(2) < 50%) (12) and the profile likelihood estimate in settings of high heterogeneity (I(2) ≥ 50%) (13).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Two independent reviewers assessed risk of bias in individual RCTs by using the criteria of Jadad and colleagues (9), as in our prior review (6).”
MethodDowns, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252 · cited 1×
“We used the Downs and Black tool for assessment of the risk of bias for the nonrandomized trials and observational studies (10).”
MethodEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“diet) on the relative benefits of metformin and sulfonylureas for the spectrum of long-term outcomes important in diabetes (32).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Research works printed but not linked: 1
- Wang CP, 2014, J Endocrinol Diabetes Obes, 2
Cited by
Items 601–700 of 733
Metformin as a potential therapy for malignant astrocytoma
Eagles, L. (2018) · Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton)
Buhse, S., & Mühlhauser, I. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_32
Grbić, A., Malešević, G., Grbić, S., Grujičić, M., & Jelača, V. (2019) · Биомедицинска истраживања · doi:10.7251/bii1901008g
Assessment of adverse drug reaction reports
Matić, I. L. (2019)
Bhattacharyya, S., & Mukherjee, B. (2019) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2019.019
The role of the heart failure nurse and use of sodium glucose cotransporter-2 inhibitors
Melville, M. (2019) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2019.0055
Xhakaza, L. (2019) · University of the Western Cape Electronic Theses and Dissertations Repository (University of the Western Cape)
DIABETES MELLITUS: THE MODERN STATE OF THE ISSUE (PART 2)
Sharofova, M. U., Самаровна, С. Ш., & Yusuf, S. D. (2019) · Avicenna Bulletin · doi:10.25005/2074-0581-2019-21-4-661-674 · Cited by 1
The role of hypoxia and metabolism in the pathogenesis of systemic sclerosis
Ottria, A. (2020) · Utrecht University Repository (Utrecht University)
Bando, H., Iwatsuki, N., Sakamoto, K., & Ogawa, T. (2020) · doi:10.52588/case-reports-medical-research.1.05
“When compared with sulfonylurea agents, it has beneficial efficacy on weight, HbA1c and cardiovascular outcomes (16).”
BackgroundWilkinson, S. (2020) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · doi:10.17037/pubs.04656434
Towards an additive manufactured macroencapsulation device for islet cell replacement therapy
Levey, R. E. (2020) · Arrow@dit (Dublin Institute of Technology) · doi:10.13025/17353
Lalau, J., Al‐Salameh, A., Wiernsperger, N. F., Goronflot, T., Pichelin, M., Wargny, M., Desailloud, R., Hadjad, S., Gourdy, P., & Cariou, B. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.013
Building therapy in type 2 diabetes – metformin and beyond
Morris, D. (2021) · Independent Nurse · doi:10.12968/indn.2021.3.14
Mubeen, S., Rehan, R., Sundus, S., Raza, I., & Jabeen, S. (2019) · Journal of Bahria University Medical and Dental College · doi:10.51985/jbumdc2019072
Edagha, I. A., Edem, D. O., Akpan, H., Usoh, I. F., & Edagha, E. I. (2020) · Archives of Diabetes and Endocrine System · doi:10.22259/2638-4981.0302005
“A first line medication for the treatment of type 2 diabetes, particularly in people who are overweight is Metformin, marketed as Glucophage® [2].”
BackgroundInfluentialHood, D. K., Ananthraman, S., & Musa, O. M. (2021) · Wiley eBooks · doi:10.1002/9781119468769.hpcbm024
Dubois, T. B. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3gt5fx4s
Peng, M., Deng, Y.-L., Yu, L. H., Nie, Y., Luo, T., Huang, J., Zhou, X., & Ding, Y. (2021) · Global Clinical and Translational Research · doi:10.36316/gcatr.03.0043
Anestesia y diabetes en el perioperatorio
Ramírez, A. Y. L., Molina, N. E. C., & García, J. P. A. O. (2021) · Anales Médicos de la Asociación Médica del Centro Médico ABC · doi:10.35366/101667 · Cited by 1
Сафроненко, А. В., Ганцгорн, Е. В., Sanina, E. A., Khachumova, M. A., Panenko, S. O., Kuznetsov, I. I., Kivva, A. A., & Полякова, В. И. (2021) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2021-9-5-377-386
“Thus, according to the results of the meta-analysis conducted in 2016 [25], it was found that metformin monotherapy was accompanied by a lower (≥2 years) mortality from complications of cardiovascular diseases compared with sulfonylurea monotherapy.”
ResultMetformin: an old drug with potential therapeutic function in antitumorPreprint
Mu, W., Jiang, Y., & Qu, F. (2021) · Authorea · doi:10.22541/au.163640852.26812577/v1
Nuevos hipoglucemiantes en el cuidado de las personas con diabetes tipo 2: por fin hay un avance
Kopitowski, K. S. (2021) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v25i1.6979
Gastroenterologische Komplikationen des Diabetes mellitus: Gastroparese
Weber, A.-L., Leitolf, H., & Wedemeyer, H. H. (2021) · Gastroenterologie up2date · doi:10.1055/a-1502-4925
“Metformin wird weiterhin als Erstlinientherapie empfohlen, da es sicher und kosteneffektiv ist und zu einer Reduktion des HbA1c-Wertes, des Gewichts sowie der kardiovaskulären Mortalität führt [15].”
BackgroundCOVID-19: Can Metformin Drastically Reduce the Number of Deaths?
Lorenzo, B. (2021) · Journal of Medical - Clinical Research & Reviews · doi:10.33425/2639-944x.1186
“We are talking about Metformin, the anti-diabetic drug par excellence [15] for type 2 diabetes mellitus, the affliction of modern times, one that usually affects obese people over 40 years of age.”
BackgroundPandya, N., & Patel, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-01782-8_38-1
Akhtar, M. S., Sharma, M., Sani, S., Kapur, P., Sharma, G., Tabassum, F., & Khan, M. F. (2022) · Current Drug Therapy · doi:10.2174/1574885517666220408110650
Pharmacodynamic Evaluation: Endocrinology
Naafs, M. A. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_35
The role of the heart failure nurse and use of sodium glucose cotransporter-2 inhibitors
Mellville, M. (2019) · Journal of Prescribing Practice · doi:10.12968/jprp.2019.1.12.602
Approach to Chronic Kidney Disease in the Diabetic Patient
Afshinnia, F., & Brosius, F. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00051-6
J, A. A., & Orekoya, E. O. (2022) · Journal of Medical Sciences(Faisalabad) · doi:10.3923/jms.2022.170.177
Chronic Kidney Disease Is a Risk Enhancer for Cardiovascular Diseases
Padalia, K. J., & Hayek, S. S. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_14 · Cited by 1
A Rare Case of Mortal Metformin Intoxication
Az, A., & Akdemir, T. (2022) · Global Emergency and Critical Care · doi:10.4274/globecc.galenos.2022.43153
Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure
Mirzazada, V., kizi, S. S. S., Ismayilova, N., Huseynova, A., Nurmammadova, G., Ismayilova, S., & Aliyeva, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106391
Metformin in the prevention of colorectal cancer with diabetes mellitus
Друк, И. В., Lyalyukova, E. A., & Fadeeva, E. A. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-205-9-161-170
Secondary Diseases of the Kidney
Natale, P., Wong, M. G., Strippoli, G. F., Tunnicliffe, D. J., Cooper, T. E., & Pollock, C. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch24
Therapeutic peptidomimetics in metabolic diseases
Sirhan, W., & Piran, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820141-1.00023-6 · Cited by 1
Effects of hypoglycaemic therapy on frailty: a multi-dimensional perspective
Abdelhafiz, A. H. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2168644 · Cited by 1
Senn, J., & Fischli, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822186-0.00014-6
Research Progress of Metformin in the Treatment of Cirrhosis with Diabetes
杨, 子. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.132315
Current Strategies of New Drugs for Diabetes Management
Sarfraz, M., Hafizur, R. M., Ullah, H., Sajid, S., Akhtar, R. W., Noreen, M., Perveen, S., & Khan, M. U. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070005
Mühlhauser, I., Buhse, S., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_34
Time to revisit the true role of metformin in type 2 diabetes mellitus
López‐Candales, A., Monte, S. V., Sawalha, K., & Norgard, N. B. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2224036
Beginning and Managing Underlying Comorbidities
Billah, Z., Chadnick, Z., Kansagra, K., Kimyaghalam, A., Madassery, S., Shinagawa, A., Singh, K., & Vatakencherry, G. (2023) · Springer eBooks · doi:10.1007/978-3-031-36480-8_4
Type 1 and Type 2 Diabetes Mellitus
Comoglio, M., Monge, L., & Longhi, E. V. (2023) · Springer eBooks · doi:10.1007/978-3-031-31307-3_11
Effects of Kenponashi-Artichoke Compound Supplement on CCl4 -induced Chronic Hepatic Injury to Rats
Chu, W.-L., Lin, W., & Yang, L.-C. (2023) · Liver Research - Open Journal · doi:10.17140/lroj-4-114
Schneider, L., Anderson, R., Chalmers, D., Doherty, S., Wootten, T., Harvey, M. G., & Cave, G. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4689669
Review on sulphonamide analogues for the perspective of antibacterial and antidiabetic activity
Mittapalli, S. K., Saquib, & Mishra, A. (2024) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2024.19.2.0022 · Cited by 1
In Vitro Drug-Drug Interaction of Metformin HCl with Omeprazole and Lansoprazole
Shereen, S. H., & Syeda Rafia Zehra Rizvi, I. S. (2024) · Journal of Hunan University Natural Sciences · doi:10.55463/issn.1674-2974.51.5.13
Wang, J., Zhao, L., Miao, X., Yang, Y., & Yangb, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4714361/v1
Saúde da Família e Comunidade - Edição I
Coelho, L. R. P. (2024) · doi:10.59290/978-65-6029-150-8
Higher Serum Dipeptidyl Peptidase-4 Activity in Newly Diagnosed Young-Onset Type 2 Diabetes Mellitus
Mahmood, T., Rahman, H., Jahan, S., Sultana, N., Hasan, M., Hasan, M. I., Shehab, M. A., Fariduddin, M., Salimullah, M., & HASANAT, M. A. (2024) · Cureus · doi:10.7759/cureus.70968
“As a result, inhibition of their degradation would aid in establishing glucose homeostasis from multiple perspectives, along with additional benefits of weight neutrality and a very low risk of hypoglycemia [8].”
Background3. Blood glucose-lowering therapies – Non-insulin options for type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112147 · Cited by 1
Song, J. H., Kim, J., Hong, J. H., Jung, J. G., Park, S. Y., & Sunwoo, J. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1532
田, 洋. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551501
Progress of Indole Alkaloids for Potential Application in Type 2 Diabetes Mellitus-An Updated Review
(2025) · Biointerface Research in Applied Chemistry · doi:10.33263/briac151.009
Chaudhuri, S., Biswas, S., Mukhopadhyay, S., & Dasgupta, S. (2025) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_492_24
Sankoh, P. S., Turay, A., & Conteh, E. B. (2025) · doi:10.38124/ijisrt/25jul454
Li, W., Huang, L., Wang, R., Peng, P., Song, A., Zeng, Y., & Zhang, Z. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70084
“7 In order to fill this knowledge gap, we accomplished a meta-analysis to pool multiple randomised controlled trials (RCTs) of the efficacy and safety of GLP-1RAs combined with metformin, classified by ethnicity, extracting data on weight reduction, fasting plasma glucose (FPG) and glycosylated…”
The Emerging Role of the Cancerous Inhibitor of Protein Phosphatase 2A in Pulmonary Diseases
Hamza, H., Nirmal, D., Pappas, S., Ebubechukwu, U. J., Gill, S., Al-Ajam, A., Ohlmeyer, M. H. J., & Geraghty, P. M. (2025) · Medicina · doi:10.3390/medicina61101740
“Metformin, a biguanide antidiabetic drug, is recommended as the first-line therapy for type 2 diabetes due to its efficacy, relative safety, and beneficial effects of reducing hemoglobin A1c (HbA1C) levels and weight, in addition to its general tolerability and favorable cost [136].”
Park, J. H., Cho, B. S., Zhou, X. B., Kyung, R., & Kim, M. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010184 · Cited by 1
Darusman, F., Sopyan, I., & Rusdiana, T. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e158758
Chaurasia, N. K., Mothashin, M., & Hossain, M. G. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02068-y · Cited by 1
Metformin: Glycemic and Extra-Glycemic Actions
Massarini, S., & Luzi, L. (2025) · Springer eBooks · doi:10.1007/978-3-032-01700-0_10
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Kroon, L. A., & Zhou, C. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch08
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Pharmacologic management of diabetes in older adults
Sia, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29025-1.00007-2
Therapeutic potential of metformin-based combination therapy in acute myeloid leukemia
Shamahmood, M. N., Miri, A., Yousefi, M. J., & Mezginejad, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-04205-4
Alshadfan, H., Mirghani, H. O., Alrasheed, T., Alanazi, M. A., & Abdullah, M. N. H. (2025) · Pan African Medical Journal · doi:10.11604/pamj.2025.52.176.49165
Incretin-based therapies in patients with Type 2 diabetes mellitus and renal impairment
Howse, P. M. (2023) · Memorial University Research Repository (Memorial University) · doi:10.48336/hems-sk50 · Cited by 1
Nazu, N. A., Wikström, K., Lamidi, M.-L., Lindström, J., Tirkkonen, H., Rautiainen, P., & Laatikainen, T. (2022) · Figshare · doi:10.6084/m9.figshare.21532609
Pelletier, R., Ng, K., Alkabbani, W., Labib, Y., Mourad, N., & Gamble, J.-M. (2021) · Figshare · doi:10.25384/sage.13653382
Longato, E., Di Camillo, B., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · Figshare · doi:10.6084/m9.figshare.12463160
EMPA-REG OUTCOME Trial : What does it mean?
Therapeutics Initiative (University of British Columbia) (2023) · cIRcle (University of British Columbia) · doi:10.14288/1.0433686
Ono, R., Ogami, C., Hasegawa, C., To, H., Matsumoto, Y., & Tsuji, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24779192
Candeias, E. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Suissa, M. (2020) · eScholarship@McGill (McGill) · doi:10.82308/23179
Föchterle, S. (2020) · University Library Linz repository (Johannes Kepler Universitat Linz)
Kumari, N., Arya, A. K., Prakash, V., Hameed, S., Mishra, H., & Dikshit, H. (2026) · Cureus · doi:10.7759/cureus.101227
“Metformin remains the cornerstone of pharmacological therapy for T2DM, recommended as first-line treatment by major guidelines due to its efficacy, safety, and cost-effectiveness [6,7].”
Feng, Y., Yu, Q., Li, H., Shen, B., Ding, J., & Hua, D. (2026) · BMC Cancer · doi:10.1186/s12885-025-15494-x
Saber, K., Ismail, R. S., Bassyouni, A., El-Shafee, M., & Hassan, M. H. (2026) · European journal of medical research · doi:10.1186/s40001-025-03816-5
“The controversy has also extended to the effect of Met on body weight [16, 53].”
Kim, S. M., Shin, W., Yang, A., Kim, A., Lee, Y.-S., Na, J., Cho, J. M., Yoon, S., & Yoo, H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-04986-7
Treatment challenges in a very high-risk diabetic patient with coronary artery disease
Andrić, D., Čanković, M., Stojšić‐Milosavljević, A., Tešić, D., Andric, S., Petrović, M., Dejanović, J., Miljković, T., & Nedeljkovic, M. A. (2020) · Srce i krvni sudovi · doi:10.5937/siks2011027a
Wan, J., Meng, C., Yue, C., Zhao, D., Li, S., Gong, Y., & Shao, Y. (2026) · Food Science and Human Wellness · doi:10.26599/fshw.2026.9250915
Effect of metformin treatment on ovarian function in hypothyroid rats
Soliman, N. A., Shalaby, A. A., Abulfadle, K. A., Mohammed, H. O., Hussien, S., Ammar, M. A. M., Metwally, A. S., & Bahaie, E. E. (2026) · Open Veterinary Journal · doi:10.5455/ovj.2026.v16.i1.37
Kajio, H., Bouchi, R., Komatsu, M., Yamazaki, M., Takarabe, D., Okamoto, M., Tanaka, T., Kitazawa, T., Katsuyama, H., Mori, Y., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70253
Dinis, R. P. D. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Besas, F. P., & Pasawa, M. (2026) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.1598823160
Guía de práctica clínica sobre Diabetes Mellitus Tipo 1
(2026) · GuíaSalud eBooks · doi:10.46995/gpc_659
Seki, H. K. (2023) · Dspace Repository (Marmara Üniversitesi)
Nutritional, phytochemical, and potential health benefits of Monostroma spp.: A systematic review
Islam, M. (2026) · Food biomacromolecules. · doi:10.1002/fob2.70054
Drug Repurposing of Aspirin and Metformin with Special Reference to Colorectal Cancer Mitigation
Talukder, P., Mukherjee, A., Sinha, B., Mishra, M., Datta, S., & Sengupta, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814533126010010
Antonelli, E., Dell’Era, A., Maconi, G., & Bassotti, G. (2026) · Metabolites · doi:10.3390/metabo16040238
“It is a widely available, well-tolerated, and safe drug, and it has a very low cost [8,10].”
Contribution des études observationnelles dans la méta-analyse
Cheurfa, C. (2023) · theses.fr (ABES) · doi:10.70675/ecaa782bz76f7z4c43za043ze1d3e0cfbfaa
Campbell, I. W., Brand, K. M. G., Gottwald‐Hostalek, U., & Dettenbach, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03592-6
“Metformin is assessed as moder‑ ately lowering weight, benefits patients safety by not causing hypoglycaemia [38, 39], and is recommended where cost‑related barriers may exist [1].”
Sinclair, A., Al-Banna, M., Tutunariu, R., & Abdelhafiz, A. H. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16040213
Ge, X., Luo, Z., Zhang, Y., Zhang, L., Wang, G., Yuan, X., Li, Q., & Zhai, X. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1744208
Alharbi, S. G., & Barnawi, R. A. (2026) · Saudi Journal for Health Sciences · doi:10.4103/sjhs.sjhs_155_25
Sambhav, K., Batham, A. K., Nimavat, A. S., Singh, R., Lodha, N., Jha, H., & Patel, A. (2026) · Cureus · doi:10.7759/cureus.108406
“Its simplicity and lower initial treatment burden are associated with improved early adherence, and pharmacoeconomic analyses indicate that it remains a cost-effective strategy in many healthcare settings [24].”
Metadata
- Authors
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S.
- Affiliations
- MetroHealth (US)
- From The Johns Hopkins University School of Medicine; The Johns Hopkins University Bloomberg School of Public Health; and Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, and Center for Health Care Research and Policy, MetroHealth/Case Western Reserve University; MetroHealth Medical Center; and Case Western Reserve University, Cleveland, Ohio.
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-06-07
- Volume
- 164
- Issue
- 11
- Pages
- 740-751
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2340898396
- Cited by
- 682
- References
- 66
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 60 · 2023: 68 · 2022: 80 · 2021: 90 · 2020: 89 · 2019: 71 · 2018: 68 · 2017: 56 · 2016: 11
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- Agency for Healthcare Research and Quality (290-2012-00007-I)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, metformin, monotherapy, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular mortality, glycemic control, HbA1c, weight loss, hypoglycemia, gastrointestinal adverse effects, genital mycotic infections, first-line therapy
- MeSH terms
- Adult, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.